

Progress Report: Sri Lanka Clinical Trials Registry

SLCTR registration number: SLCTR/2022/013

Scientific title of trial: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy

Date of commencement (enrolment of first participant): 09 Dec 2022

Progression: 6 months 1 year 2 years **X** 3 years
At completion

1. Baseline data

Any changes to the trial design/ methodology/ protocol after commencement: Yes (Protocol version 2.0 dated 16 Feb 2023)

Any changes to trial outcomes after commencement: No

2. Current status

Recruitment status:
recruitment complete: follow up continuing

Number assessed for eligibility: 15

Number recruited and allocated/randomized: 9

Number allocated/randomized to each intervention/arm (please edit as relevant):

NA

Losses/exclusions after allocation/randomization (please edit as relevant):

NA

3. Trial output

Date of trial completion ("last patient, last visit"): Not applicable

Final sample size: Not applicable

Summary of Interim/Final data (if available):

N/A

Abstract presentations of results at scientific meetings


Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).
N/A	N/A
N/A	N/A

Publications

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)
N/A	N/A
N/A	N/A



Prof. Eranga Wijewickrama

Coordinating Principal Investigator

Date: 23 Aug 2024